IMMUNOPRECISE ANTIBODIES LTD (IPA) Stock Overview
USA - NASDAQ:IPA - CA45257F2008 - Common Stock
IPA Key Statistics, Chart & Performance
The current stock price of IPA is 2.07 USD. In the past month the price increased by 14.36%. In the past year, price increased by 209.19%.
IPA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 21.59 | 178.47B | ||
| DHR | DANAHER CORP | 25.62 | 138.15B | ||
| A | AGILENT TECHNOLOGIES INC | 23.25 | 35.93B | ||
| IQV | IQVIA HOLDINGS INC | 16.28 | 31.74B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 31.15 | 26.24B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 36.87 | 18.45B | ||
| WAT | WATERS CORP | 24.83 | 18.08B | ||
| ILMN | ILLUMINA INC | 24.25 | 15.50B | ||
| TEM | TEMPUS AI INC | N/A | 15.02B | ||
| MEDP | MEDPACE HOLDINGS INC | 37.01 | 13.98B | ||
| ICLR | ICON PLC | 13.24 | 13.63B | ||
| RVTY | REVVITY INC | 17.46 | 9.91B |
Related stock screener links
About IPA
Company Profile
ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The company is headquartered in Austin, Texas. The company is advancing Bio-Native AI at the intersection of biology and computation. Its LENSai and HYFT platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. The core of its operations encompasses a diverse suite of proprietary technologies that aid in the exploration, discovery, and development of novel drugs and biologics. Integrated within its wet lab infrastructure is a diverse array of in silico technologies. As an end-to-end service provider of antibody discovery and development, its computational methodologies allow the Company to perform detailed and comprehensive evaluations across various stages of biologic discovery and development. The company is involved in antibody characterization studies, which encompass affinity measurements, epitope landscape profiling, and others.
Company Info
IMMUNOPRECISE ANTIBODIES LTD
Industrious 823 Congress Ave Suite 300
Austin TEXAS US
Employees: 102
Phone: 16048060626
IMMUNOPRECISE ANTIBODIES LTD / IPA FAQ
What is the stock price of IMMUNOPRECISE ANTIBODIES LTD today?
The current stock price of IPA is 2.07 USD. The price increased by 7.25% in the last trading session.
What is the ticker symbol for IMMUNOPRECISE ANTIBODIES LTD stock?
The exchange symbol of IMMUNOPRECISE ANTIBODIES LTD is IPA and it is listed on the Nasdaq exchange.
On which exchange is IPA stock listed?
IPA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for IMMUNOPRECISE ANTIBODIES LTD stock?
6 analysts have analysed IPA and the average price target is 5.1 USD. This implies a price increase of 146.38% is expected in the next year compared to the current price of 2.07. Check the IMMUNOPRECISE ANTIBODIES LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IMMUNOPRECISE ANTIBODIES LTD worth?
IMMUNOPRECISE ANTIBODIES LTD (IPA) has a market capitalization of 95.53M USD. This makes IPA a Micro Cap stock.
How many employees does IMMUNOPRECISE ANTIBODIES LTD have?
IMMUNOPRECISE ANTIBODIES LTD (IPA) currently has 102 employees.
What are the support and resistance levels for IMMUNOPRECISE ANTIBODIES LTD (IPA) stock?
IMMUNOPRECISE ANTIBODIES LTD (IPA) has a support level at 1.92. Check the full technical report for a detailed analysis of IPA support and resistance levels.
Is IMMUNOPRECISE ANTIBODIES LTD (IPA) expected to grow?
The Revenue of IMMUNOPRECISE ANTIBODIES LTD (IPA) is expected to grow by 13.46% in the next year. Check the estimates tab for more information on the IPA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy IMMUNOPRECISE ANTIBODIES LTD (IPA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IPA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IPA, evaluating the profitability, health, valuation and growth aspects
- IMMUNOPRECISE ANTIBODIES LTD (IPA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IMMUNOPRECISE ANTIBODIES LTD (IPA) Sales and EPS estimates to see what analysts future expectations are.
- IMMUNOPRECISE ANTIBODIES LTD (IPA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IMMUNOPRECISE ANTIBODIES LTD (IPA) Insider and Institutional Ownership to learn about the owners and their transactions.
- IMMUNOPRECISE ANTIBODIES LTD (IPA) Stock Chart to make your own analysis
- IMMUNOPRECISE ANTIBODIES LTD (IPA) Latest news and press-releases to stay up to date.
Does IMMUNOPRECISE ANTIBODIES LTD (IPA) stock pay dividends?
IPA does not pay a dividend.
When does IMMUNOPRECISE ANTIBODIES LTD (IPA) report earnings?
IMMUNOPRECISE ANTIBODIES LTD (IPA) will report earnings on 2025-12-08.
What is the Price/Earnings (PE) ratio of IMMUNOPRECISE ANTIBODIES LTD (IPA)?
IMMUNOPRECISE ANTIBODIES LTD (IPA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.22).
What is the Short Interest ratio of IMMUNOPRECISE ANTIBODIES LTD (IPA) stock?
The outstanding short interest for IMMUNOPRECISE ANTIBODIES LTD (IPA) is 0.86% of its float. Check the ownership tab for more information on the IPA short interest.
IPA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to IPA. When comparing the yearly performance of all stocks, IPA is one of the better performing stocks in the market, outperforming 98.62% of all stocks.
IPA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IPA. IPA may be in some trouble as it scores bad on both profitability and health.
IPA Financial Highlights
Over the last trailing twelve months IPA reported a non-GAAP Earnings per Share(EPS) of -0.22. The EPS increased by 34.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -68.03% | ||
| ROE | -127.97% | ||
| Debt/Equity | 0.49 |
IPA Forecast & Estimates
6 analysts have analysed IPA and the average price target is 5.1 USD. This implies a price increase of 146.38% is expected in the next year compared to the current price of 2.07.
For the next year, analysts expect an EPS growth of 49.5% and a revenue growth 13.46% for IPA